Nasdaq: REGN
Regeneron Pharmaceuticals insiders
The officers, directors and 10% owners of Regeneron Pharmaceuticals, Inc. who hold the most stock, valued at the live REGN price.
$923.34
REGN today −$22.2M (−2.35%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 18
- Their REGN stock
- $3.80B
- Market value
- $95.52B
- Held by ranked insiders
- 3.98%
Insiders by value of REGN holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | Leonard S. Schleifer | Bd. Co-Chair, President & CEO | 2,398,771 | $2.21B | 2.32% | 141st |
| 2 | George Yancopoulos | Bd. Co-Chair, President & CSO | 925,945 | $855M | 0.90% | 312th |
| 3 | P. Roy Vagelos | Director | 467,104 | $431M | 0.45% | 529th |
| 4 | Neil E. Stahl | EVP Research and Development | 59,283 | $54.7M | <0.1% | 2374th |
| 5 | Andrew Murphy | Co-Chief Scientific Officer | 51,193 | $47.3M | <0.1% | 2647th |
| 6 | Joseph LaRosa | EVP General Counsel and Secret | 48,128 | $44.4M | <0.1% | 2766th |
| 7 | Daniel P. Van Plew | EVP & General Mgr, Industrial | 35,178 | $32.5M | <0.1% | 3545th |
| 8 | George L. Sing | Director | 25,297 | $23.4M | <0.1% | 4625th |
| 9 | Christopher R. Fenimore | EVP Finance CFO | 25,224 | $23.3M | <0.1% | 4637th |
| 10 | Robert E. Landry | EVP Finance CFO | 23,963 | $22.1M | <0.1% | 4735th |
| 11 | Arthur F. Ryan | Director | 17,303 | $16.0M | <0.1% | 6117th |
| 12 | Michael S. Brown | Director | 12,865 | $11.9M | <0.1% | 7716th |
| 13 | Marion McCourt | EVP Commercial | 10,524 | $9.7M | <0.1% | 8972nd |
| 14 | Joseph L. Goldstein | Director | 6,703 | $6.2M | <0.1% | 12489th |
| 15 | Christine A. Poon | Director | 5,219 | $4.8M | <0.1% | 7643rd |
| 16 | Marc Tessier-Lavigne | Director | 2,434 | $2.2M | <0.1% | 3118th |
| 17 | Bonnie L. Bassler | Director | 1,703 | $1.6M | <0.1% | 11424th |
| 18 | David P. Schenkein | Director | 603 | $557K | <0.1% | 6200th |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Regeneron Pharmaceuticals; see each profile for the filing.